Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment – Reuters

  1. Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment  Reuters
  2. Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate  GlobeNewswire
  3. Why GLP-1s Won’t Be Prescribed for Alzheimer’s Anytime Soon  Oprah Daily
  4. Semaglutide’s Alzheimer’s miss. Plus: Vaccine policy, funding for cell, gene therapies  BioCentury
  5. Oral semaglutide fails to slow Alzheimer’s in pair of clinical trials  Alzheimer’s News Today

Continue Reading